Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 11/20 | 0.59 |
| ▸ | THRB | P10828 | 11/20 | 0.59 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.55 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.55 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731049 | 1.00 | THRA (0.59) | THRATHRBHSD17B3HAO1RARB | |
| SCHEMBL903614 | 0.90 | THRA (0.65) | THRATHRBHAO1RARB | |
| SCHEMBL11440891 | 0.85 | THRA (0.79) | THRATHRBHSD17B3HAO1RARB | |
| SCHEMBL2724731 | 0.83 | ALDH1A1 (0.61) | HAO1RARB | |
| SCHEMBL901008 | 0.83 | ALDH1A1 (0.61) | HAO1RARB | |
| SCHEMBL2725127 | 0.83 | ALDH1A1 (0.49) | THRATHRBHAO1RARB | |
| SCHEMBL8479392 | 0.82 | HSD17B3 (0.69) | THRATHRBHSD17B3HAO1 | |
| SCHEMBL9138023 | 0.81 | THRA (0.72) | THRATHRBHSD17B3HAO1RARB | |
| SCHEMBL9075808 | 0.80 | THRA (0.70) | THRATHRBHSD17B3HAO1 | |
| SCHEMBL9075714 | 0.80 | THRA (0.70) | THRATHRBHSD17B3HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632889-B1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD (IL) | 2018-08-29 | — | — | EP | disclosed |
| EP-3092222-B1 | IMPROVED FINGOLIMOD PROCESS | EMCURE PHARMACEUTICALS LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3092222-A1 | IMPROVED FINGOLIMOD PROCESS | Emcure Pharmaceuticals Limited (IN) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015107548-A1 | IMPROVED FINGOLIMOD PROCESS | EMCURE PHARMACEUTICALS LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| US-8735627-B2 | Intermediate compounds and process for the preparation of fingolimod | MAPI PHARMA LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| US-8735627-B2 | Intermediate compounds and process for the preparation of fingolimod | MAPI PHARMA LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2013-08-22 | — | — | US | disclosed |
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2013-08-22 | — | — | US | disclosed |
| WO-2011159870-A9 | METHODS AND COMPOUNDS FOR THE PREPARATION OF FLUORINE-LABELED DEOXY-FTY720 | BRACCO IMAGING S.P.A. (IT) | 2012-04-12 | — | — | WO | disclosed |
| WO-2011159870-A1 | METHODS AND COMPOUNDS FOR THE PREPARATION OF FLUORINE-LABELED DEOXY-FTY720 | BRACCO IMAGING S.P.A. (IT) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | S1PR2, S1PR4, S1PR3 | THRA 3775/4885THRB 3565/4885HSD17B3 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.